The vasopressin analogue terlipressin has been associated with improved renal fuction in patients with HRS, its effect on survival is unknown. Aim: To evaluate the effectiveness of an infusion of terlipressin plus albumin in revesing HRS, its tolerability, its adverse effects. Methods: 1/2011-7/2013, 27 consecutive patients with cirrhosis patients and HRS were indude in the study (11 patients typ 1, 16 patients typ 2). All patient received Terlipressin by continous IV at the dose 3mg/24 h plus albumin (20g/24h) as treatment for HRS. Response to treatment were defined by decrease in serum creatinin 133umol/l or decrease in pretreatment peak serum creatinin20 percent at the end treatment. Results: At inclusion, the Child Pugh score was 12,91 + or - 5,34, MELD 33,56 + or - 8,71. Renal function improved in 40,74 percent of patients. After treatment, serum creatinin decreased by 36,3 percent, urin output significantly increase progrressively, Creatinin clearance improve in response groups. Median survival time was 101 days for responses groups, 8,2 days for non responses groups. Survival rate was 37,04 percent at month, 22,2 percent at 2 months. Conclusion: The study shows that in patients with HRS terlipressin induced improved renal function is associated with an increase in survival.
- Đăng nhập để gửi ý kiến